 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
Enrollment closed: FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Oct 26, 2023
P2, N=180, Active, not recruiting, Sponsor: Abliva AB
Recruiting --> Active, not recruiting
- ||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
Enrollment open: FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Jan 30, 2023
P2, N=180, Recruiting, Sponsor: Abliva AB
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
New P2 trial: FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Dec 14, 2022
P2, N=180, Not yet recruiting, Sponsor: Abliva AB
- || KL1333 / Abliva, Yungjin Pharma
BioStock: Celebrating IND approval Abliva eyes next step with KL1333 https://t.co/l5Bn2eCL5o (Twitter) - Mar 7, 2022
- ||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
Trial completion: A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Oct 20, 2021
P1a/1b, N=72, Completed, Sponsor: Abliva AB
Not yet recruiting --> Recruiting Recruiting --> Completed
- || 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
Trial completion: Drug-drug Interaction Study of KL1333 in Healthy Subjects (clinicaltrials.gov) - Oct 19, 2021
P1, N=14, Completed, Sponsor: Abliva AB
Recruiting --> Completed Recruiting --> Completed
- | 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
New P1 trial: Drug-drug Interaction Study of KL1333 in Healthy Subjects (clinicaltrials.gov) - Nov 24, 2020
P1, N=14, Recruiting, Sponsor: Abliva AB
- || 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
Trial completion date, Trial primary completion date: A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Oct 14, 2020
P1a/1b, N=72, Recruiting, Sponsor: NeuroVive Pharmaceutical AB
Recruiting --> Completed Trial completion date: Mar 2020 --> Feb 2021 | Trial primary completion date: Mar 2020 --> Jan 2021
- ||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
New P1 trial: A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - Mar 25, 2019
P1a/1b, N=72, Recruiting, Sponsor: NeuroVive Pharmaceutical AB
- ||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, Yungjin Pharm
Trial completion: Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers (clinicaltrials.gov) - Apr 27, 2018
P1, N=60, Completed, Sponsor: Yungjin Pharm. Co., Ltd.
Trial completion date: Mar 2020 --> Feb 2021 | Trial primary completion date: Mar 2020 --> Jan 2021 Recruiting --> Completed
- || 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, Yungjin Pharm
Trial completion date, Trial primary completion date: Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers (clinicaltrials.gov) - Mar 3, 2018
P1, N=80, Recruiting, Sponsor: Yungjin Pharm. Co., Ltd.
Recruiting --> Completed Trial completion date: Mar 2018 --> Apr 2018 | Trial primary completion date: Mar 2018 --> Apr 2018
- ||| 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, Yungjin Pharm
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers (clinicaltrials.gov) - Dec 21, 2017
P1, N=80, Recruiting, Sponsor: Yungjin Pharm. Co., Ltd.
Trial completion date: Mar 2018 --> Apr 2018 | Trial primary completion date: Mar 2018 --> Apr 2018 Not yet recruiting --> Recruiting | N=10 --> 80 | Initiation date: Mar 2017 --> Jun 2017 | Trial primary completion date: Jun 2017 --> May 2018
- 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, Yungjin Pharm
New P1 trial: Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers (clinicaltrials.gov) - Feb 16, 2017
P1, N=10, Not yet recruiting, Sponsor: KT&G Life Sciences Corp